ExodusPoint Capital Management LP acquired a new stake in shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP – Get Rating) in the third quarter, according to its most recent disclosure with the SEC. The firm acquired 362,544 shares of the biopharmaceutical company’s stock, valued at approximately $60,000. ExodusPoint Capital Management LP owned approximately 0.29% of Corbus Pharmaceuticals at the end of the most recent reporting period.
A number of other institutional investors have also added to or reduced their stakes in the stock. Vident Investment Advisory LLC boosted its position in shares of Corbus Pharmaceuticals by 66.2% during the 1st quarter. Vident Investment Advisory LLC now owns 255,146 shares of the biopharmaceutical company’s stock valued at $135,000 after acquiring an additional 101,659 shares during the last quarter. State Street Corp boosted its position in shares of Corbus Pharmaceuticals by 10.7% during the 1st quarter. State Street Corp now owns 395,513 shares of the biopharmaceutical company’s stock valued at $210,000 after acquiring an additional 38,304 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of Corbus Pharmaceuticals by 40.6% during the 2nd quarter. Renaissance Technologies LLC now owns 1,626,860 shares of the biopharmaceutical company’s stock valued at $410,000 after acquiring an additional 469,669 shares during the last quarter. 18.65% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of research analysts have recently commented on CRBP shares. HC Wainwright reiterated a “buy” rating and set a $3.00 target price on shares of Corbus Pharmaceuticals in a research report on Tuesday, February 14th. StockNews.com assumed coverage on Corbus Pharmaceuticals in a research report on Monday, February 20th. They set a “sell” rating for the company.
Corbus Pharmaceuticals Stock Down 1.0 %
About Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its products include candidate, Lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes.
- Get a free copy of the StockNews.com research report on Corbus Pharmaceuticals (CRBP)
- MarketBeat Week in Review – 2/27 – 3/3
- The 3 Most Upgraded Stocks Are Reversing
- How to Find Blue Chip Dividend Stocks
- Zscaler, Inc Plummets, Is It Time To Buy The Dip?
- What is a Good Dividend Yield? How to Decide
Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.